Crystal Mackall: a cell therapy innovator’s view on decision-making

With three spinouts under her belt, Stanford University professor Crystal Mackall aims to leverage academia’s critical role in de-risking cell and gene therapies to safeguard the advancement of programs for pediatric and rare diseases.

The co-founder of Lyell Immunopharma Inc. (NASDAQ:LYEL), Cargo Therapeutics Inc. and Link Cell Therapies Inc. was trained in internal medicine and pediatrics at Northeastern Ohio College of Medicine, now known as NeoMed, before launching a 27-year career of bench-to-bedside cancer immunotherapy research at NIH, where she was chief of the Pediatric Oncology Branch and head of the Immunology Section...